Technical Analysis for OVID - Ovid Therapeutics Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Down | Down |
| See historical OVID trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Narrow Range Bar | Range Contraction | -3.35% | |
| NR7 | Range Contraction | -3.35% | |
| Wide Bands | Range Expansion | -3.35% | |
| Oversold Stochastic | Weakness | -3.35% | |
| Narrow Range Bar | Range Contraction | -2.53% | |
| Wide Bands | Range Expansion | -2.53% | |
| Oversold Stochastic | Weakness | -2.53% | |
| Narrow Range Bar | Range Contraction | -3.35% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.
Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Genodermatoses Sedatives Anticonvulsants Fragile X Syndrome Syndromes
Biopharmaceutical Organ Systems Disorders Neurological Disorders Epilepsy Genodermatoses Sedatives Anticonvulsants Fragile X Syndrome Syndromes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more OVID news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 6.14 |
| 52 Week Low | 1.53 |
| Average Volume | 588,284 |
| 200-Day Moving Average | 2.2031 |
| 50-Day Moving Average | 2.3278 |
| 20-Day Moving Average | 2.7025 |
| 10-Day Moving Average | 2.331 |
| Average True Range | 0.2388 |
| ADX | 25.77 |
| +DI | 26.099 |
| -DI | 23.1683 |
| Chandelier Exit (Long, 3 ATRs ) | 3.2536 |
| Chandelier Exit (Short, 3 ATRs ) | 2.8064 |
| Upper Bollinger Band | 3.6016 |
| Lower Bollinger Band | 1.8034 |
| Percent B (%b) | 0.28 |
| BandWidth | 66.53839 |
| MACD Line | -0.0389 |
| MACD Signal Line | 0.0252 |
| MACD Histogram | -0.0641 |
| Fundamentals | Value |
|---|---|
| Market Cap | 56.83 Million |
| Num Shares | 24.6 Million |
| EPS | -4.85 |
| Price-to-Earnings (P/E) Ratio | -0.48 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 1.52 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.52 | ||||
| Resistance 3 (R3) | 2.54 | 2.49 | 2.49 | ||
| Resistance 2 (R2) | 2.49 | 2.44 | 2.48 | 2.47 | |
| Resistance 1 (R1) | 2.40 | 2.40 | 2.38 | 2.38 | 2.46 |
| Pivot Point | 2.35 | 2.35 | 2.34 | 2.34 | 2.35 |
| Support 1 (S1) | 2.26 | 2.30 | 2.24 | 2.24 | 2.16 |
| Support 2 (S2) | 2.21 | 2.26 | 2.20 | 2.15 | |
| Support 3 (S3) | 2.12 | 2.21 | 2.14 | ||
| Support 4 (S4) | 2.10 |
